SINTX TECHNOLOGIES ANNOUNCES APPOINTMENT OF MARK I. FROIMSON, M.D., TO ITS BOARD OF DIRECTORS
March 02 2020 - 7:00AM
SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”),
an original equipment manufacturer (OEM) ceramics company focused
on silicon nitride applications, today announced the appointment of
Mark I. Froimson, M.D. to its board of directors.
Dr. Froimson is currently a Principal at
Riverside Health Advisors, a consulting company that provides
strategic advice and services to health care executive leaders. Dr.
Froimson served as past President of the American Association of
Hip and Knee Surgeons, and as the Executive Vice President and
Chief Clinical Officer of Trinity Health, a national non-profit
Catholic healthcare system comprising 93 hospitals in 22
states.
Prior to the position at Trinity Health, Dr.
Froimson was President and CEO of Euclid Hospital, a part of the
Cleveland Clinic system. Dr. Froimson served as a staff surgeon in
the Department of Orthopedic Surgery at the Cleveland Clinic for
over 16 years, during which time he held many leadership positions
including Medical Staff President, Vice Chair of the Orthopedic and
Rheumatologic Institute, and member of the Board of Governors and
Board of Trustees. Dr. Froimson serves on the Board of Directors of
Pacira Biosciences, Inc., a publicly traded company on the NASDAQ
Stock Market, and on the national Board of Directors of the
Arthritis Foundation.
“Mark’s clinical expertise, leadership, and
proven track record of driving medical innovation, and extensive
contacts in the orthopaedic medical device space will complement
SINTX’s expansion of its technology platform beyond spine, toward
arthroplasty applications,” said Dr. Sonny Bal, chairman and chief
executive officer of SINTX. “We welcome Mark and look forward to
his contributions to SINTX.”
“SINTX’s proprietary technology, and unsurpassed
research, promise to unleash the potential of silicon nitride for
additional medical and healthcare applications. Given the
compelling evidence of the superior antimicrobial properties of
this material, there promises to be an increased role in procedures
that would benefit from a reduction in rates of surgical site
infection,” Froimson noted. “I am thrilled to be joining this
industry leading team that is poised to make significant inroads in
an industry looking for meaningful innovations that can benefit
patients.”
Dr. Froimson received a B.A. in philosophy from
Princeton University, an M.D. from Tulane University School of
Medicine, and an MBA from the Weatherhead School of Business at
Case Western Reserve University. He completed his general surgical
and orthopedic training at the University of California, Los
Angeles and Columbia-Presbyterian Medical Center. He completed his
fellowship in adult reconstructive surgery at the University
Hospitals of Cleveland.
Dr. Froimson’s publications include several book
chapters, and numerous abstracts and articles in scientific
journals, including the Journal of Arthroplasty and the Journal of
Bone and Joint Surgery. In addition, he serves in an editorial
capacity for numerous scientific publications and is an
internationally sought-after speaker and consultant on healthcare
economics and business practices.
About SINTX Technologies,
Inc.
SINTX Technologies is an OEM ceramics company
that develops and commercializes silicon nitride for medical and
non-medical applications. The core strength of SINTX Technologies
is the manufacturing, research, and development of silicon nitride
ceramics for external partners. The Company presently manufactures
silicon nitride spinal implants in its FDA registered and ISO 13485
certified manufacturing facility for CTL-Amedica, the exclusive
retail channel for silicon nitride spinal implants.
For more information on SINTX
Technologies or its silicon nitride material platform, please visit
www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (PSLRA) that are subject to a number of risks
and uncertainties. Risks and uncertainties that may cause such
differences include, among other things, the uncertainties inherent
in research and development, including the cost and time required
advance our products to regulatory submission; market acceptance of
our products once cleared and commercialized; our ability to raise
additional funding and other competitive developments. Readers are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date on which they are made
and reflect management’s current estimates, projections,
expectations and beliefs. There can be no assurance that any of the
anticipated results will occur on a timely basis or at all due to
certain risks and uncertainties, a discussion of which can be found
in SINTX’s Risk Factors disclosure in its Annual Report on Form
10-K, filed with the Securities and Exchange Commission (SEC) on
March 11, 2019, and in SINTX’s other filings with the SEC. SINTX
disclaims any obligation to update any forward-looking statements.
SINTX undertakes no obligation to publicly revise or update the
forward-looking statements to reflect events or circumstances that
arise after the date of this report.
Contact:SINTX
Technologies801.839.3502IR@sintx.com
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Mar 2024 to Apr 2024
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Apr 2023 to Apr 2024